InsidersTradesSigma
Biomarin Pharmaceutical INC Stock: price and insider trades · United States · SEC (Form 4)
Track the Biomarin Pharmaceutical INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Biomarin Pharmaceutical INC has recorded 262 reports. Market capitalisation: €10.9bn. The latest transaction was disclosed on 21 May 2026 (Retenue fiscale). Among the most active insiders: BIENAIME JEAN JACQUES. Every trade is openly available.
262
Insider Decl.
0
Thresholds
€315,890
1 ops.
Buy Volume
€17m
43 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Biomarin Pharmaceutical INC Buy (bullish), based on 26 analysts. Average price target: US$87.85.
38Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 9,894 of 25,514 companies
57.7
score / 100
Value48
Quality68
FCF yld6.1%
Earn yld3.0%
EV/EBITDA21.4x
ROE4.5%
Gross mgn78%
Net mgn11%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 21 May 2026
Declarations262 total
2,318 shares@ US$50.200.0009% mcap44.0% of flowCommon StockSEC:0001628280-26-037455:0
375 shares@ US$54.1371.8% of flowCommon StockSEC:0001628280-25-054856:0
16,570 shares@ US$55.0378.1% of flowCommon StockSEC:0001628280-25-054856:1
7,000 shares0Common StockSEC:0001048477-25-000095:0
6,650 shares0Common StockSEC:0001048477-25-000070:0
6,650 shares0Common StockSEC:0001048477-25-000062:0
6,650 shares0Common StockSEC:0001048477-25-000064:0
6,650 shares0Common StockSEC:0001048477-25-000076:0
2,155 shares@ US$59.9350.3% of flowCommon StockSEC:0001048477-25-000080:0
6,650 shares0Common StockSEC:0001048477-25-000074:0
6,650 shares0Common StockSEC:0001048477-25-000066:0
6,650 shares0Common StockSEC:0001048477-25-000078:0
6,650 shares0Common StockSEC:0001048477-25-000068:0
996 shares@ US$59.277.9% of flowCommon StockSEC:0001048477-25-000060:0
273 shares@ US$54.1375.7% of flowCommon StockSEC:0001048477-25-000053:0
1,295 shares@ US$71.5212.7% of flowCommon StockSEC:0001048477-25-000041:0
16,249 shares@ US$69.4410.4% of flowCommon StockSEC:0001048477-25-000037:0
13,310 shares0Common StockSEC:0001048477-25-000035:0
823 shares@ US$69.447.9% of flowCommon StockSEC:0001048477-25-000039:0
2,933 shares@ US$69.4418.6% of flowCommon StockSEC:0001048477-25-000027:0
18,497 shares@ US$69.4424.2% of flowCommon StockSEC:0001048477-25-000029:0
17,750 shares0Common StockSEC:0001048477-25-000033:0
20,127 shares@ US$69.4440.6% of flowCommon StockSEC:0001048477-25-000031:0
7,034 shares@ US$71.27614.7% of flowCommon StockSEC:0001048477-25-000025:0
25 of 262 declarations
About Biomarin Pharmaceutical INC
BioMarin Pharmaceutical Inc. is a U.S.-based biopharmaceutical company focused on rare and ultra-rare genetic diseases. The shares trade on the NASDAQ under the ticker BMRN in the United States. Headquartered in San Rafael, California, with important operations in Novato, BioMarin was founded in 1997 and originally built its franchise around enzyme technology for genetically defined disorders. Over time, the company evolved into a broader rare-disease platform combining discovery, development, commercialization, and lifecycle expansion of specialized therapies. For investors, BioMarin sits in the quality-growth segment of healthcare: it is not a large diversified pharma group, but a focused specialist with deep scientific expertise and a commercially established rare-disease portfolio. The company’s business model centers on medicines for severe, often lifelong genetic conditions where treatment options are limited and clinical differentiation matters. Its marketed products include VOXZOGO for achondroplasia, PALYNZIQ for phenylketonuria, and a set of established enzyme replacement therapies such as BRINEURA, NAGLAZYME, VIMIZIM, KUVAN, and ALDURAZYME, alongside certain sapropterin-related franchises depending on market and formulation. This portfolio gives BioMarin a meaningful commercial base and supports a recurring-revenue profile, while also leaving room for upside from label expansions, new launches, and pipeline execution. Its competitive position is that of a global rare-disease leader: the company competes on scientific specialization, regulatory know-how, and the ability to operate in small, medically urgent markets where payer access and specialist physician adoption are critical. BioMarin organizes its strategy around three business units: Enzyme Therapies, Skeletal Conditions, and ROCTAVIAN. Geographically, it has a broad international footprint with commercial and operating activity across North America, Europe, Japan, Brazil, and other regions, reflecting the global nature of its rare-disease franchises. Recent developments have been notable. In 2025, BioMarin reported positive data and pursued regulatory expansion for PALYNZIQ in adolescents, completed its acquisition of Inozyme in July 2025 to strengthen its rare-disease portfolio, and later reported solid 2025 operating results together with a growth plan built around portfolio expansion, clinical readouts, and additional indication opportunities. For French-speaking investors, BioMarin offers a niche global healthcare exposure with a mix of established products, pipeline optionality, and strategic M&A-driven growth, all within a U.S.-listed NASDAQ name.
